Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 48 articles:
HTML format
Text format



Single Articles


    May 2018
  1. MEHTA PP, Kung PP, Yamazaki S, Walls M, et al
    Retraction notice to "A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells".
    Cancer Lett. 2018;422:132.
    PubMed     Text format    


  2. ZHENG Y, Wang K, Wu Y, Chen Y, et al
    Pinocembrin induces ER stress mediated apoptosis and suppresses autophagy in melanoma cells.
    Cancer Lett. 2018;431:31-42.
    PubMed     Text format     Abstract available


    March 2018
  3. MARSAVELA G, Aya-Bonilla CA, Warkiani ME, Gray ES, et al
    Melanoma circulating tumor cells: Benefits and challenges required for clinical application.
    Cancer Lett. 2018;424:1-8.
    PubMed     Text format     Abstract available


  4. TANG J, Zhou H, Hou X, Wang L, et al
    Enhanced anti-tumor efficacy of temozolomide-loaded carboxylated poly(amido-amine) combined with photothermal/photodynamic therapy for melanoma treatment.
    Cancer Lett. 2018;423:16-26.
    PubMed     Text format     Abstract available


    January 2018
  5. MIRZAEI H, Salehi H, Oskuee RK, Mohammadpour A, et al
    The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model.
    Cancer Lett. 2018 Jan 10. pii: S0304-3835(18)30051.
    PubMed     Text format     Abstract available


  6. DI GENNARO P, Gerlini G, Caporale R, Sestini S, et al
    T regulatory cells mediate immunosuppresion by adenosine in peripheral blood, sentinel lymph node and TILs from melanoma patients.
    Cancer Lett. 2018 Jan 3. pii: S0304-3835(18)30005.
    PubMed     Text format     Abstract available


    November 2017
  7. RODRIGUEZ CI, Castro-Perez E, Longley BJ, Setaluri V, et al
    Elevated cyclic AMP levels promote BRAF(CA)/Pten(-/-) mouse melanoma growth but pCREB is negatively correlated with human melanoma progression.
    Cancer Lett. 2017 Nov 24. pii: S0304-3835(17)30749.
    PubMed     Text format     Abstract available


    September 2017
  8. AIDA S, Sonobe Y, Tanimura H, Oikawa N, et al
    MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30555.
    PubMed     Text format     Abstract available


  9. HUANG GX, Wang Y, Su J, Zhou P, et al
    Up-regulation of Rho-associated kinase 1/2 by glucocorticoids promotes migration, invasion and metastasis of melanoma.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30552.
    PubMed     Text format     Abstract available


  10. KIM SJ, Jung KH, Son MK, Park JH, et al
    Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
    Cancer Lett. 2017;403:339-353.
    PubMed     Text format     Abstract available


    August 2017
  11. RUZZOLINI J, Peppicelli S, Andreucci E, Bianchini F, et al
    Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.
    Cancer Lett. 2017 Aug 18. pii: S0304-3835(17)30487.
    PubMed     Text format     Abstract available


  12. WANG J, Hirose H, Du G, Chong K, et al
    P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway.
    Cancer Lett. 2017 Aug 10. pii: S0304-3835(17)30478.
    PubMed     Text format     Abstract available


    July 2017
  13. CALERO R, Morchon E, Martinez-Argudo I, Serrano R, et al
    Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
    Cancer Lett. 2017 Jul 31. pii: S0304-3835(17)30457.
    PubMed     Text format     Abstract available


  14. PERES J, Maliepaard EM, Rambow F, Larue L, et al
    The tumour suppressor, miR-137, inhibits malignant melanoma migration by targetting the TBX3 transcription factor.
    Cancer Lett. 2017 Jul 28. pii: S0304-3835(17)30454.
    PubMed     Text format     Abstract available


  15. CIMAS FJ, Callejas-Valera JL, Garcia-Olmo DC, Hernandez-Losa J, et al
    E1a is an exogenous in vivo tumour suppressor.
    Cancer Lett. 2017;399:74-81.
    PubMed     Text format     Abstract available


  16. BORST A, Haferkamp S, Grimm J, Rosch M, et al
    Involvement of the BH3-only pro-apoptotic BIK/NBK in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
    Cancer Lett. 2017 Jul 15. pii: S0304-3835(17)30431.
    PubMed     Text format     Abstract available


  17. KUZU OF, Gowda R, Sharma A, Noory MA, et al
    Improving Pharmacological Targeting of AKT in Melanoma.
    Cancer Lett. 2017 Jul 10. pii: S0304-3835(17)30419.
    PubMed     Text format     Abstract available


  18. CALAPRE L, Warburton L, Milward M, Ziman M, et al
    Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
    Cancer Lett. 2017 Jul 4. pii: S0304-3835(17)30412.
    PubMed     Text format     Abstract available


    June 2017
  19. KLIMKIEWICZ K, Weglarczyk K, Collet G, Paprocka M, et al
    A 3D model of tumour angiogenic microenvironment to monitor hypoxia effects on cell interactions and cancer stem cell selection.
    Cancer Lett. 2017;396:10-20.
    PubMed     Text format     Abstract available


  20. LEE YK, Park UH, Kim EJ, Hwang JT, et al
    Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.
    Cancer Lett. 2017 Jun 17. pii: S0304-3835(17)30396.
    PubMed     Text format     Abstract available


    April 2017
  21. WANG Y, Liu M, Jin Y, Jiang S, et al
    In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
    Cancer Lett. 2017 Apr 26. pii: S0304-3835(17)30289.
    PubMed     Text format     Abstract available


  22. LUO C, Shen J
    Research progress in advanced melanoma.
    Cancer Lett. 2017 Apr 3. pii: S0304-3835(17)30219.
    PubMed     Text format     Abstract available


  23. HOU X, Zhou H, Wang L, Tang J, et al
    Multifunctional near-infrared dye-magnetic nanoparticles for bioimaging and cancer therapy.
    Cancer Lett. 2017;390:168-175.
    PubMed     Text format     Abstract available


    February 2017
  24. XU DH, Zhu Z, Xiao H, Wakefield MR, et al
    Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
    Cancer Lett. 2017 Feb 28. pii: S0304-3835(17)30131.
    PubMed     Text format     Abstract available


  25. GUTTERIDGE RE, Singh CK, Ndiaye MA, Ahmad N, et al
    Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
    Cancer Lett. 2017 Feb 22. pii: S0304-3835(17)30121.
    PubMed     Text format     Abstract available


  26. DE SOUZA LM, Robertson BM, Robertson GP
    Future of Circulating Tumor Cells in the Melanoma Clinical and Research Laboratory Settings.
    Cancer Lett. 2017 Feb 2. pii: S0304-3835(17)30064.
    PubMed     Text format     Abstract available


    January 2017
  27. PEARLMAN RL, Montes de Oca MK, Pal HC, Afaq F, et al
    Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.
    Cancer Lett. 2017 Jan 25. pii: S0304-3835(17)30070.
    PubMed     Text format     Abstract available


    October 2016
  28. CHOLEWA BD, Ndiaye MA, Huang W, Liu X, et al
    Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cancer Lett. 2016 Oct 25. pii: S0304-3835(16)30646.
    PubMed     Text format     Abstract available


  29. GOWDA R, Sharma A, Robertson GP
    Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
    Cancer Lett. 2016 Oct 18. pii: S0304-3835(16)30628.
    PubMed     Text format     Abstract available


    September 2016
  30. LEE DG, Choi BK, Kim YH, Oh HS, et al
    The repopulating cancer cells in melanoma are characterized by increased mitochondrial membrane potential.
    Cancer Lett. 2016 Sep 5. pii: S0304-3835(16)30512.
    PubMed     Text format     Abstract available


    July 2016
  31. XU S, Wang H, Pan H, Shi Y, et al
    ANRIL lncRNA triggers efficient therapeutic efficacy by reprogramming the aberrant INK4-hub in melanoma.
    Cancer Lett. 2016 Jul 25. pii: S0304-3835(16)30441.
    PubMed     Text format     Abstract available


    May 2016
  32. LU Y, Wang Y, Miao L, Haynes M, et al
    Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Cancer Lett. 2016 May 25. pii: S0304-3835(16)30338.
    PubMed     Text format     Abstract available


  33. BETTI M, Aspesi A, Biasi A, Casalone E, et al
    CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
    Cancer Lett. 2016 May 12. pii: S0304-3835(16)30306.
    PubMed     Text format     Abstract available


    April 2016
  34. MATSUO K, Itoh T, Koyama A, Imamura R, et al
    CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma.
    Cancer Lett. 2016 Apr 28. pii: S0304-3835(16)30275.
    PubMed     Text format     Abstract available


  35. DASHTI A, Ebrahimi M, Hadjati J, Memarnejadian A, et al
    Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses.
    Cancer Lett. 2016;374:175-85.
    PubMed     Text format     Abstract available


  36. XIAO D, Barry S, Kmetz D, Egger M, et al
    Melanoma cell-derived exosomes promote epithelial-mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment.
    Cancer Lett. 2016 Apr 7. pii: S0304-3835(16)30211.
    PubMed     Text format     Abstract available


  37. JORDAN M, Waxman DJ
    CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
    Cancer Lett. 2016;373:88-96.
    PubMed     Text format     Abstract available


    March 2016
  38. DENG L, Fan J, Guo M, Huang B, et al
    Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Cancer Lett. 2016;372:251-7.
    PubMed     Text format     Abstract available


  39. ZHU G, Yi X, Haferkamp S, Hesbacher S, et al
    Combination with gamma-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
    Cancer Lett. 2016 Mar 18. pii: S0304-3835(16)30178.
    PubMed     Text format     Abstract available


    January 2016
  40. TANG R, Xu X, Yang W, Yu W, et al
    MED27 promotes melanoma growth by targeting AKT/MAPK and NF-kappaB/iNOS signaling pathways.
    Cancer Lett. 2016 Jan 18. pii: S0304-3835(16)00017.
    PubMed     Text format     Abstract available


    December 2015
  41. CHEUNG M, Kadariya Y, Talarchek J, Pei J, et al
    Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.
    Cancer Lett. 2015;369:261-5.
    PubMed     Text format     Abstract available


  42. COSTANTINO VV, Lobos-Gonzalez L, Ibanez J, Fernandez D, et al
    Dehydroleucodine inhibits tumor growth in a preclinical melanoma model by inducing cell cycle arrest, senescence and apoptosis.
    Cancer Lett. 2015 Dec 21. pii: S0304-3835(15)00740.
    PubMed     Text format     Abstract available


  43. DE AGUIAR RB, Parise CB, Souza CR, Braggion C, et al
    Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings.
    Cancer Lett. 2015 Dec 3. pii: S0304-3835(15)00720.
    PubMed     Text format     Abstract available


    November 2015
  44. LI Z, Jiang K, Zhu X, Lin G, et al
    Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells.
    Cancer Lett. 2015 Nov 14. pii: S0304-3835(15)00689.
    PubMed     Text format     Abstract available


    August 2015
  45. NOGUCHI S, Mori T, Igase M, Mizuno T, et al
    A novel apoptosis-inducing mechanism of 5-aza-2'-deoxycitidine in melanoma cells: demethylation of TNF-alpha and activation of FOXO1.
    Cancer Lett. 2015 Aug 31. pii: S0304-3835(15)00563.
    PubMed     Text format     Abstract available


  46. WANG Z, Cheng Q, Tang K, Sun Y, et al
    Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells.
    Cancer Lett. 2015;364:118-24.
    PubMed     Text format     Abstract available


    June 2015
  47. BETTUM IJ, Gorad SS, Barkovskaya A, Pettersen S, et al
    Metabolic reprogramming supports the invasive phenotype in malignant melanoma.
    Cancer Lett. 2015 Jun 18. pii: S0304-3835(15)00398.
    PubMed     Text format     Abstract available


  48. YANG X, Du T, Wang X, Zhang Y, et al
    IDH1, a CHOP and C/EBPbeta-responsive gene under ER stress, sensitizes human melanoma cells to hypoxia-induced apoptosis.
    Cancer Lett. 2015 Jun 3. pii: S0304-3835(15)00377.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: